Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

The aging kidney revisited: A systematic review

(2014) Davide Bolignano et al.   AGEING RESEARCH REVIEWS

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients

(2011) M. S. Marcolino et al.   ANNALS OF ONCOLOGY

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease

(2011) M. Iyoda et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Dysregulation of bone remodeling by imatinib mesylate

(2009) K. Vandyke et al.   BLOOD

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia

(2009) A. Al-Kali et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature

(2009) Anat Gafter-Gvili et al.   LEUKEMIA RESEARCH

A New Look at Platelet-Derived Growth Factor in Renal Disease

(2007) J. Floege et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY